Symptoms of anxiety and depression and risk of heart failure: the HUNT Study

Lise T. Gustad1,2*, Lars E. Laugsand3, Imre Janszky3,4, Håvard Dalen1,5, and Ottar Bjerkneset2,6

1Department of Internal Medicine, Nord-Trøndelag Hospital Trust, Levanger Hospital, Levanger, Norway; 2Department of Neuroscience, Norwegian University of Technology and Science (NTNU), Trondheim, Norway; 3Department of Public Health and General Practice, NTNU, Trondheim, Norway; 4Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden; 5Department of Circulation and Medical Imaging, NTNU, Trondheim, Norway; and 6Faculty of Health Sciences, Nord-Trøndelag University College (HiNT), Levanger, Norway

Received 15 April 2014; revised 5 June 2014; accepted 13 June 2014; online publish-ahead-of-print 12 July 2014

Aims
Symptoms of anxiety and depression often co-exist with cardiovascular disease, yet little is known about the prospective risk for heart failure (HF) in people with symptoms of depression and anxiety. We aimed to study these prospective associations using self-reported symptoms of anxiety, depression, and mixed symptoms of anxiety and depression (MSAD) in a large population sample.

Methods and results
In the second wave of the Nord-Trøndelag Health Study (HUNT 2, 1995–1997), Norway, baseline data on symptoms of anxiety and depression, socio-demographic variables, health status including cardiovascular risk factors, and common chronic somatic diseases were registered for 62,567 adults, men and women, free of known HF. The cohort was followed for incident HF from baseline throughout 2008. A total of 1499 cases of HF occurred during a mean follow-up of 11.3 years (SD = 2.9), identified either in hospital registers or by the National Cause of Death Registry. There was no excess risk for future HF associated with symptoms of anxiety or MSAD at baseline. For depression, the multi-adjusted hazard ratios for HF were 1.07 (0.87–1.30) for moderate symptoms and 1.41 (1.07–1.87) for severe symptoms (P for trend 0.026). Established cardiovascular risk factors, acute myocardial infarction (AMI) prior to baseline, and adjustment for incident AMI as a time-dependent covariate during follow-up had little influence on the estimates.

Conclusion
Symptoms of depression, but not symptoms of anxiety or MSAD, were associated with increased risk for HF in a dose–response manner. The increased risk could not be fully explained by cardiovascular or socio-economic risk factors, or by co-morbid AMI.

Keywords
Depression • Anxiety • Prospective • Risk • Heart failure • Epidemiology

Introduction
Heart failure (HF) is often co-prevalent with symptoms of depression1–8 and anxiety,9,10 and symptoms of depression have been found to worsen the course and prognosis of established HF.11,12

Ischaemic heart disease (IHD), like acute myocardial infarction (AMI), is the main cause of HF in Europe and accounts for ~60% of HF.13 Other known precursors for HF are hypertension, diabetes, cardiomyopathy, heart valve disease, and arrhythmias.14 In the development of HF, except HF initiated by AMI, the process of myocardial remodelling often starts long before the onset of HF symptoms.15 As HF is a major and increasingly important public health problem, it is crucial to search for modifiable risk factors in the aetiology of HF.16 It is plausible that symptoms of depression and anxiety represent such modifiable risk factors as they have been found to influence behavioural risk factors for HF, such as obesity, reduced physical activity, alcohol abuse, and smoking.17,18 Furthermore, neurohormonal stress associated with symptoms of depression and anxiety is known to regulate blood pressure, heart

*Corresponding author. Department of Internal Medicine, Levanger Hospital, Kirkegata 2, 7600 Levanger, Norway. Tel: +47 410 44 326, Fax: +47 74 09 85 90, Email: lise.t.gustad@ntnu.no or lise.tuset.gustad@gmail.com

© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
rate, proinflammatory cytokines, and circulating catecholamine levels, which in turn promote HF.\textsuperscript{1,16}

However, the prospective evidence supporting a link between symptoms of depression and future HF arise from small studies of elderly people, and the results are conflicting.\textsuperscript{4-8} To the best of our knowledge, only one study, among US veterans, has investigated the risk for future HF with symptoms of anxiety.\textsuperscript{17} We therefore aimed to investigate the prospective association of self-reported symptoms of anxiety and depression with risk for future HF in a large population-based study, taking into account a large number of established cardiovascular risk factors, previous and/or incident AMI, several chronic somatic disorders, and previous symptoms of anxiety and depression.

**Methods**

**Study population and setting**

All adult citizens in Nord-Trøndelag County, Norway, received a postal invitation to participate in the second wave of the Nord-Trøndelag Health Study (HUNT 2, 1995–1997, http://www.ntnu.edu/hunt). In total, 94,187 individuals were invited, and 65,215 (69%) participated in the HUNT 2 study. The participants attended a baseline clinical examination and gave self-report on standardized questionnaires (http://www.ntnu.edu/hunt/data/qeq). Details of the HUNT study have been published elsewhere.\textsuperscript{18,19}

The study was approved by the regional committee for medical and health research ethics, by the National Directorate of Health, and by the Norwegian Data Inspectorate.

**Exposure: symptoms of anxiety and depression**

Participants self-reported symptoms of anxiety and depression using a Norwegian version of the Hospital Anxiety and Depression Scale (HADS),\textsuperscript{20} which assesses core psychological symptoms of anxiety (HADS-A) and depression (HADS-D) during the previous week.

Seven depression questions mirror symptoms of anhedonia and loss of interest, and seven anxiety questions mirror mostly symptoms of worry and tension. We included all participants that responded to \geq 5 items on one subscale (n = 62,693). For those who filled in only five or six items on the HADS-A and -D subscales, missing scores were substituted based on the sum of completed items multiplied by 7/5 or 7/6, respectively.\textsuperscript{21} All HADS questions have a 4-point Likert scale, ranging from 0 (no symptom) to 3 (highest symptom level); thus the subscales range from 0 points (no symptoms) to 21 points, which allows calculation of risk per unit increase in the HADS.\textsuperscript{21} In addition, recommended cut-offs were used to categorize the participants as not depressed or anxious (score \leq 8), moderately depressed or anxious (score between 8 and 11), and severely depressed or anxious (score \geq 11).\textsuperscript{22} Mixed symptoms of anxiety and depression (MSAD) were calculated by summing up valid HADS-A and HADS-D into HADS-total scores (HADS-T) and categorized into no MSAD (score \leq 15), moderate MSAD (score between 15 and 18), and severe MSAD (score \geq 19).\textsuperscript{23}

Previous symptoms of MSAD were available for 36,418 participants that also attended HUNT 1 (1984–1986) and filled in the 4-item Anxiety and Depression Index (ADI-4). ADI-4 has a high correlation (0.83) with the HADS-T score from HUNT 2 and is an acceptable indicator for MSAD (sensitivity 0.51, specificity 0.93).\textsuperscript{24} Two ADI questions have a 4-point Likert scale: calmness, ranging from almost all the time (1) to never (4); and nervousness, ranging from never (1) to almost all the time (4). The last two ADI questions about mood and vitality have a 7-point Likert scale ranging from very happy/strong and fit (1) to very downhearted/tired and worn out (7). We categorized symptoms of MSAD in HUNT 1 by scoring on the upper quartile on ADI-4, i.e above a score of 14. Symptoms of MSAD in HUNT 2 were defined as a score \geq 19 on the HADS-T subscale. A variable to indicate the combined burden of MSAD in HUNT 1 and 2 was created in categories of never (no symptoms of MSAD in HUNT 1 or 2), one (MSAD symptoms in one of the HUNT waves), and two episodes (MSAD symptoms in both HUNT waves).

**Outcome ascertainment**

After baseline, the participants were followed up for a first incident of HF until 31 December 2008, identified either by linkage with medical records at the two hospitals in Nord-Trøndelag county or by the National Cause of Death Registry.\textsuperscript{25} A total of 126 participants were excluded because their medical records indicated HF before they participated at baseline. Therefore, 62,567 people were included in the analyses, as displayed in Figure 1. Heart failure was defined and diagnosed according to the current European Society of Cardiology (ESC) Guidelines.\textsuperscript{26} The overall quality of the hospital discharge diagnosis of HF is generally high in Nordic countries.\textsuperscript{27,28} In order to increase specificity, we only extracted primary diagnoses as recommended.\textsuperscript{27} Deaths due to HF were extracted from the National Death Registry. We used International Classification of Diseases (ICD) 9 code 428 and ICD codes 150.0, 150.1, and 150.9 to identify HF.\textsuperscript{25} Having 100% specificity and low—but non-differential—sensitivity leads to no bias of the risk ratio. Even a slight decrease in specificity, even if non-differential, might lead to a severe bias. Therefore, in brief, our decision to include only primary diagnosis decreases our power, but preserved our validity.\textsuperscript{29}

During an average of 11.3 years of follow-up, 8164 participants who died of causes other than HF and 224 who left the county were censored at time of death or emigration (see Figure 1).

**Covariates**

**Demographic and lifestyle factors**

Cohabitation status was dichotomized as living with a partner or alone. Education was categorized as low (\leq 9 years), medium (between 10 and 12 years), or high (over 12 years).

Smoking habits were self-reported and were categorized as current, previous, or never smoking. We categorized the participants according to self-reported alcohol consumption as abstainers, very light drinkers (\leq 1 drinks per day), light to moderate drinkers (1–2 drinks per day), or moderate to heavy drinkers (>2 drinks per day). Physical activity was reported as light or hard, defined respectively as activity excluding or including sweating or feelings of breathlessness. The participants were categorized as inactive (<1 h of strenuous activity and <3 h of light physical activity per week), moderately active (1–3 h of strenuous activity or >3 h of light activity per week), and as physically active (>3 h of strenuous physical activity per week).

**Common chronic somatic diseases**

The participants reported their medical history (yes/no) regarding previous cardiovascular diseases (myocardial infarction, stroke, or angina

\textcopyright 2014 The Authors. *European Journal of Heart Failure* published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Symptoms of anxiety and depression and risk of heart failure

Clinicalexaminationswereperformedbytrainednursesaccordingtoa
standardized protocol and included measurements of blood pressure,
heart rate, weight, height, and waist and hip circumference. Heart rate,
systolic and diastolic blood pressures were measured after the
participant had been seated for at least 2 min with the cuff on, with cuff
size adjusted for arm circumference. Blood pressure and heart rate
measurements were performed with the Dinamap 845XT (Criticon)
based on oscillometry and automatically involved three recordings at
1-min intervals. The first heart rate recording was on average 2 b.p.m.
lower than the second and third measurement and was thus used
in order to mirror resting heart rate. For blood pressure, the value
decreased for each recording, thus we used the average of the second
and third blood pressure readings. Height was measured without shoes
to the nearest 1.0 cm and weight with light clothing to the nearest
0.5 kg. Body mass index (BMI) was computed as weight (in kg) divided
by the squared value of height (in metres).

Blood sampling and laboratory measurements
A non-fasting whole blood sample was drawn from each partici-

© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Statistical analysis

We used Cox proportional hazard models to examine the associations of symptoms of depression and anxiety with subsequent risk for HF and hazard ratios (HRs) with 95% confidence intervals (CIs). All the models were analysed both using a categorical approach and estimating risk per unit increase on the different HADS scores. For test of trends between increasing anxiety and depression symptom level, a numeric value of 0–2 was assigned to the HADS categories, with 0 having no, 1 having moderate, and 2 having severe symptoms of anxiety or depression, treating the categories as a continuous variable. In a separate analysis, we calculated the risk for HF associated with the presence of MSAD in HUNT 1 and HUNT 2 when those without symptoms of MSAD in both of the surveys constituted the reference group.

We used directed acyclic causal graphs to summarize visually hypothetical relationships among variables of interest.29 Model 1, adjusted for age as a continuous variable and sex, is the best for assessing causality. Models 2–5 include variables that may act as both confounding and mediating factors for the association of depression and anxiety with HF risk. Model 2 included potentially socio-economic confounders, such as education and marital status. In model 3, established cardiovascular risk factors such as high heart rate, high blood pressure, low physical activity, high BMI, smoking, dyslipidaemia, alcohol intake, diabetes mellitus, and serum creatinine were added. Model 4 tested whether AMI prior to baseline data collection influenced the estimates. Finally, the full multivariable model tested if AMI during follow-up influenced the estimates, and included AMI during follow-up as a time-dependent variable (model 5). For the 2522 non-responders on the HADS questionnaire, we examined HF incidence and the distribution of the variables included in the statistical models.

Several stratified analyses were conducted to assess whether the association of anxiety and depression and risk for HF could be modified by other factors. We investigated the potential effect of modification by sex, age (dichotomized at age 50 and age 65). BMI (dichotomized at ≥35 kg/m²), total cholesterol (dichotomized at 6.5 mmol/L), education (dichotomized at 12 years), blood pressure (systolic blood pressure dichotomized at >140 mmHg, diastolic blood pressure at >90 mmHg), smoking status (current vs. no current smoking), alcohol consumption (heavy drinking vs. no heavy drinking), and previous AMI (yes/no). We also formally tested the homogeneity of stratum-specific relative risks. For these tests of interaction, we used the trend variable as defined above.

Several sensitivity analyses were performed to test the robustness of our findings. First, as AMI is a known risk factor for HF and is also associated with depression and anxiety symptoms, we performed an additional analysis restricted to those without known AMI at baseline. Next, we analysed the risk restricted to diabetic patients. Thereafter, we excluded participants with one or more of the following co-morbid physical illnesses: previous myocardial infarction (AMI), stroke, angina pectoris, cancer, asthma, diabetes mellitus, other endocrine disorders, musculoskeletal disorders, autoimmune diseases, and other chronic diseases.

Secondly, in additional analysis, we restricted cases to those HF cases that were confirmed at the hospital; thus, cases whose HF diagnosis were based on death certificates alone were excluded from the analyses.

Finally, in order to address the possibility of reverse causation as an explanation for possible associations, we excluded the first 5 years of follow-up and repeated the analyses. All sensitivity analyses were run in the full multivariable model including previous AMI and adjustment for incident AMI during follow-up as a time-dependent covariate.

We tested the proportionality of hazard using log–log curves and formal tests of interaction with time or log-time. There was no evidence against the proportionality assumption in our models. Statistical analyses were performed in Stata IC/12.1 for Windows (©Stata Corp LP).

Results

Characteristics of the study population at baseline, by HF status during follow-up, are shown in Table 1. Among those who did not respond to the HADS questionnaire, the HF incidence in the 11.4 years was 8.7%, probably mainly because they were older (mean 66.4 years) at baseline, and in addition had a more unfavourable cardiovascular risk profile, including higher blood pressure on average, than the total study population. Among the 63 567 study participants, 1499 participants (2.4%) developed HF during an average of 11.3 years (SD 2.9) of follow up. Of these, 1245 HF cases were diagnosed and included in the hospital registers, and 254 were registered by the National Cause of Death Registry alone. The participants that developed HF were older at baseline examination and more likely to have diabetes, higher systolic and diastolic blood pressure, be inactive, to live alone, have lower education, be alcohol abstainers, and score higher on the HADS-D subscale. They also had a higher incidence of incident AMI (14%) during follow-up, compared with those who did not develop HF (2.5% incident AMI).

Using the highest cut-off (HADS ≥11), the prevalence rates were 3.2% and 5.1% for depression and anxiety symptoms, respectively. This estimate is comparable with the prevalence of diagnosed depression and anxiety disorders in the general population in Europe.31 These participants were more likely to be female, less educated, inactive, current smokers, alcohol abstainers, and report a history of previous AMI than those in the reference group.

Table 2 presents the age- and sex-adjusted HRs and several multivariable adjusted HRs for incident HF in relation to symptoms of depression, anxiety, and MSAD. There was no excess risk for future HF associated with symptoms of anxiety in the crude model, adjusted for sex and age (HR 1.17, 95% CI 0.90–1.15). For MSAD, the moderately increased risk for HF observed in model 1 (HR 1.34, 95% CI 1.04–2.07) was explained by traditional cardiovascular factors in model 3 (HR 1.09, 95% CI 0.81–1.46). For depression, the age- and sex-adjusted HRs for HF were 1.11 (0.95–1.30) for moderate symptoms and 1.46 (1.19–1.80) for severe symptoms (P for trend 0.000). These associations for severe symptoms were only slightly attenuated after further adjustments for socio-economic status, an established cardiovascular risk factor (HR 1.37, 95% CI 1.04–1.81). Additional adjustment for previous and time-dependent incident AMI during follow-up did not further attenuate the risk for HF associated with severe symptoms of depression (HR 1.41, 95% CI 1.07–1.87). The results from the analysis using the risk per unit HADS score approach did not differ from the categorical approach; taking HADS-D as an example, with a 1.03 increased risk associated with each unit rise in HADS-D.
score, a person with a score of 8 will have 1.03^2 times, i.e 30%, increased risk compared with a person that scores 0. Figure 2 shows the Kaplan–Meier curves for incident HF according to depression symptom categories; depressive symptoms were associated with higher risk for HF in a dose–response manner consistently during the follow-up.

Table 3 displays the risk for HF with MSAD in HUNT 1 and 2. Those who reported MSAD in both HUNT 1 and 2 had an HR of 1.47 (95% CI 1.04–2.07) for HF in model 1 compared with those who did not experience MSAD in any of the health surveys. This relative risk for HF was, however, largely explained by cardiovascular risk factors (HR 1.18, 95% CI 0.73–1.87). Further adjustments for previous AMI and time-dependent incident AMI during follow up did not lead to further attenuation.

We found no statistical evidence for any effect modification for any of the stratified variables including sex, age, education, smoking status, BMI, total cholesterol, physical activity, and blood pressure.

### Sensitivity analysis

Supplementary material online, Table S1 presents the multivariable adjusted HRs for HF in relation to symptoms of depression, anxiety, and MSAD in different sensitivity analyses.

A total of 52202 participants completed the questionnaire on common chronic somatic disease. Of these, 16072 reported having at least one chronic somatic disease. Diabetes was six-fold more prevalent in those who later developed HF, and this warranted a separate analysis; in the 1750 diabetic participants, ≥11
Table 2 Hazard ratios (95% confidence intervals) for heart failure during follow-up according to symptoms of depression and anxiety, and mixed symptoms of anxiety and depression in HUNT 2 (1995–1997).

| Variable     | Model 1 Events/person-years | Model 2 Events/person-years | Model 3 Events/person-years | Model 4 Events/person-years | Model 5 Events/person-years |
|--------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| HADS-D       |                             |                             |                             |                             |                             |
| 0–7          | 1492/703766                 | 1310/679612                 | 905/597200                  | 900/596868                  | 900/596868                  |
| 8–10         | 1.11 (0.95–1.30)            | 1.10 (0.93–1.30)            | 1.07 (0.87–1.32)            | 1.07 (0.87–1.31)            | 1.08 (0.88–1.33)            |
| ≥11          | 1.46 (1.19–1.80)            | 1.51 (1.21–1.89)            | 1.38 (1.04–1.83)            | 1.41 (1.06–1.86)            | 1.41 (1.07–1.87)            |
| P for trend  | 0.000                       | 0.001                       | 0.034                       | 0.028                       | 0.023                       |
| Risk per unit increase in the HADS-D scale | 1.03 (1.02–1.05) | 1.03 (1.02–1.05) | 1.03 (1.01–1.05) | 1.03 (1.01–1.05) | 1.03 (1.01–1.05) |
| HADS-A       |                             |                             |                             |                             |                             |
| 0–7          | 1366/693483                 | 1224/671888                 | 869/593199                  | 864/592694                  | 864/592694                  |
| 8–10         | 1.12 (0.93–1.34)            | 1.15 (0.95–1.40)            | 0.88 (0.69–1.13)            | 0.88 (0.69–1.13)            | 0.90 (0.70–1.15)            |
| ≥11          | 1.17 (0.90–1.15)            | 1.07 (0.80–1.43)            | 0.95 (0.67–1.35)            | 0.98 (0.69–1.40)            | 1.00 (0.70–1.43)            |
| P for trend  | 0.105                       | 0.221                       | 0.431                       | 0.560                       | 0.643                       |
| Risk per unit increase in the HADS-A scale | 1.01 (0.99–1.03) | 1.01 (0.99–1.02) | 1.01 (0.99–1.03) | 1.01 (0.99–1.03) | 1.01 (0.99–1.03) |
| HADS-T       |                             |                             |                             |                             |                             |
| 0–15         | 1359/691950                 | 1219/670617                 | 868/592540                  | 869/592035                  | 863/592035                  |
| 15–19        | 1.09 (0.90–1.33)            | 1.17 (0.91–1.37)            | 1.18 (0.92–1.49)            | 1.15 (0.90–1.46)            | 1.16 (0.91–1.48)            |
| ≥19          | 1.34 (1.04–2.07)            | 1.31 (1.04–1.66)            | 1.10 (0.82–1.48)            | 1.18 (0.87–1.58)            | 1.20 (0.89–1.61)            |
| P for trend  | 0.018                       | 0.015                       | 0.248                       | 0.151                       | 0.114                       |
| Risk per unit increase in the HADS-T scale | 1.01 (1.00–1.02) | 1.01 (1.00–1.02) | 1.01 (0.99–1.02) | 1.01 (1.00–1.02) | 1.01 (1.00–1.03) |

HADS, Hospital Anxiety and Depression Scale. HADS-T, was calculated by summing up valid HADS-A and HADS-D into HADS-total scores. Model 1: adjusted for calendar age and sex. Model 2: model 1 + marital status, education. Model 3: model 2 + smoking, physical activity, body mass index, total cholesterol, diabetes mellitus, resting heart rate, systolic blood pressure, alcohol, serum creatinine. Model 4: model 3 + previous myocardial infarction. Model 5: model 4 + time-dependent adjustment for acute myocardial infarction during follow-up.

Figure 2 Kaplan–Meier curve of incident heart failure during follow-up according to depression category. HADS-D, Hospital Anxiety and Depression Scale, depression subscale.

Discussion

In this large prospective study of a general population free from known HF at baseline, we found that symptoms of depression, but not those of anxiety or MSAD, were associated with a dose–response increased risk for incident HF. This risk remained essentially unchanged after adjustment for demographic variables, established cardiovascular risk factors, previous AMI, and time-dependent adjustment for incident AMI during follow-up. The diseases related to symptoms of depression slightly increased. Of special interest, the risk associated with symptoms of depression, after excluding participants with self-reported previous AMI before HUNT 2 (n = 1253), was only reduced by ∼10% (HR 1.33, 95% CI 0.88–2.01) in the full multivariable model including adjustment for time-dependent incident AMI during follow-up.

When follow-up was restricted to HF events confirmed in hospitals (1073 events) and HF cases emerging after the first 5 years of follow-up (692 events), the risk for HF related to symptoms of depression remained virtually unchanged. The risk for HF associated with MSAD in HUNT 2 and repeated MSAD in HUNT 1 and 2 was elevated in hospitalized confirmed HF compared with the total HF sample, and lower after exclusion of the first 5 years of follow-up.
Symptoms of anxiety and depression and risk of heart failure

Table 3  Hazard ratios (95% confidence intervals) for heart failure during follow-up according to episodes of mixed symptoms of anxiety and depression in HUNT 1 and HUNT 2.

| No. of episodes of MSAD | Model 1          | Model 2          | Model 3          | Model 4          | Model 5          |
|------------------------|------------------|------------------|------------------|------------------|------------------|
| Events/person-years    | 1021/406071      | 910/392118       | 654/344334       | 651/29616        | 651/29616        |
| Never MSAD             | Reference        | Reference        | Reference        | Reference        | Reference        |
| MSAD once              | 1.12 (0.98–1.27) | 1.09 (0.95–1.24) | 1.03 (0.88–1.20) | 1.05 (0.89–1.22) | 1.05 (0.90–1.23) |
| MSAD twice             | 1.47 (1.04–2.01) | 1.53 (1.06–2.20) | 1.30 (0.83–2.06) | 1.21 (0.76–1.93) | 1.21 (0.76–1.93) |
| P for trend            | 0.018            | 0.048            | 0.441            | 0.426            | 0.385            |

MSAD, mixed symptoms of anxiety and depression.
Model 1: adjusted for calendar-age and sex.
Model 2: model 1 + marital status, education.
Model 3: model 2 + smoking, physical activity, body mass index, total cholesterol, diabetes mellitus, resting heart rate, systolic blood pressure, alcohol, serum creatinine.
Model 4: model 3 + previous myocardial infarction.
Model 5: model 4 + time-dependent adjustment for acute myocardial infarction during follow-up.

association also remained robust in several additional sensitivity analyses.

Comparison with previous studies

Previously, the association between anxiety symptoms and future HF has been investigated in one study of American veterans, where the authors found a 1.19 (95% CI 1.10–1.28) increased age-adjusted hazard associated with anxiety disorders and post-traumatic stress disorder. This point estimate is comparable with the 1.17 (95% CI 0.90–1.15) hazard for future HF associated with a score of ≥11 on the HADS-A subscale in our study. The US study has a larger sample size, with 236 079 participants, which may explain the difference in precision between the two studies.

Symptoms of depression and risk for future HF have mostly been investigated in smaller studies and/or in selected samples, and conclusions have been conflicting. Two studies found negative results between symptoms of depression and HF: the first of these was the ‘Established population for epidemiologic studies of the elderly’ (EPESE, n = 1749), conducted in 1999. However, in that study, Chen et al. seem to have discarded symptoms of depression as a risk factor for HF based on P-values from χ² and t-statistics, which do not account for time to event. The second negative results were reported in 2011 from ‘The cardiovascular health study (CHS)’ population, who at baseline were on average 79 years old but free of HF (n = 4114). Afro-American people reported more depression (30%) compared with white people (18.7%) in the CHS study, yet the distribution of confirmed HF events between the ethnic groups was not reported. Based on well known differences in health status and access to health services across ethnic groups in the USA, this is a limitation of the otherwise well performed study. In contrast, we had a homogenous study population from Norway, where healthcare coverage is universal, and free healthcare system access exists across socio-economic groups.

Conversely, three small-scale studies with potential methodological problems reported increased risk for HF with depressive symptoms. ‘The Finland, Italy and Netherlands Elderly’ (FINE study), which included only men (n = 799), found a 1.16 increased hazard for each five steps in the Zung depression rating scale. Another study, ‘the Systolic Hypertension in the Elderly Program’ in the USA, had short follow-up of 4538 persons above 65 years with hypertension, i.e inclusion of only persons predisposed for HF, found a 2.59 increased risk for future HF. The third study, also from EPESE, found a 52% increased risk for future HF associated with symptoms of depression, but only for the women in the sample. In contrast, our study included a large community sample with both sexes and long follow-up which allowed for exclusion of the first 5 years of follow-up, which increases the possibility of detecting reverse causation. Further, we used statistical models that allowed for time to event and we tested our model carefully for violations against the proportionality of hazard assumptions.

Unfavourable socio-economic and behavioural lifestyles may be a link between symptoms of depression and increased HF risk. Symptoms of depression, but not as much symptoms of anxiety, are often strongly associated with traditional risk factors for HF, such as lower education, physical inactivity, unhealthy diet, obesity, and poorer lifestyle. Some of these behaviours associated with lowered mood, such as inactivity, obesity, and smoking, are also suggested to be sources of an inflammatory process that can cause HF, and reciprocally also cause depression. In our study, people with the most severe symptoms of anxiety and depression had a more unfavourable socio-economic and cardiovascular profile. However, the adjustment for socio-economic factors and established cardiovascular risk factors only attenuated the relative risks in relation to symptoms of anxiety and MSAD, but not for depressive symptoms.

Ischaemic heart disease is a major cause of HF, and IHD is closely linked to symptoms of depression. However, in our analyses, cardiovascular risk factors and AMI prior to baseline explained only 10–13% of the risk point estimate for HF in association with depressive symptoms. Time-dependent adjustment for incident AMI during follow-up did not attenuate the risk any further. Other chronic somatic diseases did not explain the association either; and the risk for HF associated with symptoms of depression increased when we excluded these chronic disorders. In diabetic patients, for example, the crude risk for HF associated with depression symptoms was high (70%) but, after adjustment for cardiovascular...
risk factors, only a 23% increased risk remained. It is well known that over a certain amount of time, the strength of the effect of a given factor on disease occurrence may change because the prevalence of its causal complement in various mechanisms also changes. It is therefore likely that participants with chronic diseases such as diabetes have different distributions of the other component causes, i.e. cardiovascular risk factors, compared with the general population.

**Strengths and study limitations**

The large sample size and the life span perspective, together with long follow-up are amongst the most important strengths of this study. Furthermore, the HUNT catchment area has a low net migration (<0.3% net migration/year) and close to complete follow-up at the local hospitals.

Nevertheless, the study also has some important limitations. Similar to other prospective studies of risk for HF associated with symptoms of depression, we did not assess depression and anxiety disorders, but relied on self-reported symptoms. The HADS questionnaire, which was used in HUNT, does not mirror somatic symptoms of depression, we did not assess depression and anxiety, and HF risk.

The Norwegian prescription registry was established in 2004, and the HUNT 2 study does not have access to reliable data about all participants’ medications. It is important to distinguish treatment by tricyclic antidepressant which are known to cause adverse cardiovascular effects from by selective serotonin reuptake inhibitors (SSRIs) that are associated with effects that are favourable in lowering cardiovascular risk. Therefore, poor medical adherence might be a potential mechanism that remained undetected in our study. However, in the only large-scale study of risk for HF with major depressive disorder, the observed age-adjusted risk of 1.21 (1.13–1.28) increased to 1.56 with adjustment for psychotropics. The same US study also found a protective effect of psychotropics for symptoms of anxiety and MSAD, where the point estimate increased for 1.19 to 1.46 and 1.24 to 1.74, respectively. Also for depressive symptoms, other studies indicate that treatment including psychotropics protects depressed persons for future cardiovascular disease risk rather than confounding the relationship.

Increased neurohormonal stress activity and inflammation have also been linked to development of depression. Symptoms of depression may in turn up-regulate and worsen the neurohormonal regulation of heart rate, blood pressure, and obesity, which are all central mechanisms in the development of HF. In contrast, anxiety symptoms showed a weaker association with future HF in the current cohort. It may be hypothesized that low intensity anxiety, such as worry and tension, as measured by HADS-A, activates proinflammatory cytokines or neurohormonal stress activity less than diagnostic categories of anxiety, such as panic disorders and agoraphobic disorder. These latter conditions manifest with intense physiological activation and are found to increase overall morbidity. Furthermore, symptoms of anxiety often act as a precursor for depressive symptoms, and of the two conditions depression is often found to be the largest driving factor in mortality studies. Unfortunately, the HUNT study did not analyse markers of increased neurohormonal activity, and inflammatory activity was only analysed for a small subpopulation; therefore, we were not able to test these hypothetical links between depressive symptoms and future HF.

Identification and ascertainment of HF diagnostics might be misclassified. However, the overall quality and reliability of the hospital discharge registers of HF is high in Nordic Countries. In line with Nordic recommendations and to ensure optimal precision, only those with a primary diagnosis of HF were included in the analyses. From January 1995 to December 2008, a total of 1958 patients (≥18 years of age) were diagnosed with HF in the two hospitals of Nord-Trøndelag County. Of these, only 29 (1.6%) were diagnosed outside the Departments of Internal Medicine/Cardiology. Thus, 98.4% of the total HF patients received their hospital diagnosis in a setting where cardiologists were central in the diagnostics, ensuring a high sensitivity and specificity. Data from the Cause of Death Registry have somewhat lower reliability than the hospital discharge register of the HF diagnosis, as many of these deaths are probably sudden. However, even if we do not know which proportion of the deaths were sudden, we obtained essentially the same effect by restricting the study to hospital-verified HF cases, and therefore it seems unlikely that the lower reliability of HF deaths could explain our findings.

**Conclusion**

Symptoms of depression, but not symptoms of anxiety or MSAD, were associated with increased risk for HF in a dose–response manner in this general population sample. The increased risk could not be directly explained by established cardiovascular risk factors or by prevalent or incident AMI. Prevention and treatment strategies for depressive symptoms might have the potential to reduce development of cardiovascular disease, including HF, and should therefore be carried out on a population level and in primary care settings, not only in patients with established HF or cardiovascular disorders. In both community and hospital samples, anxiety often co-exists and worsens the course of depressive symptoms, and it is recommended to consider both conditions when planning appropriate management strategies.

**Acknowledgements**

The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of
Medicine, Norwegian University of Science and Technology NTNU), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. We also thank the Department for Research and Development and the Department of Internal Medicine, at Nord Trøndelag Hospital Trust, for extracting the data from hospital records.

Supplementary Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Risk for HF Associated with Symptoms of Anxiety and Depression in Sensitivity Analyses.

Funding

L.T.G. and I.J. are supported by the Liaison Committee between the Central Norway Regional Health Authority. I.J. is also supported by the Swedish Research Council for Health, Working Life and Welfare. The funders played no role in the research planning, design, or interpretation.

Conflict of interest: none declared.

References

1. Nair N, Farmer C, Gongora E, Dehmer GJ. Commonality between depression and heart failure. Am J Cardiol 2012;109:768–772.
2. Rutherford T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48:1527–1537.
3. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226–1233.
4. Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med 2001;161:1725–1730.
5. Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999;106:605–612.
6. Kamphuis MH, Kalmijn S, Tijhuis MA, Geerlings MJ, Giampaoli S, Nissinen A, Grobbee DE. Kromhout D. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (FINE) study. Eur J Cardiovasc Prev Rehabil 2006;13:199–206.
7. van den Broek KC, Defilippi CR, Christenson RH, Seliger SL, Gottdiener JS, Kop WJ. Predictive value of depressive symptoms and B-type natriuretic peptide for new-onset heart failure and mortality. Am J Cardiol 2011;107:723–729.
8. Williams SA, Karl SV, Heist A, Abramson JL, Krumholz HM, Vaccarino V. Depression and risk of heart failure among the elderly: a prospective community-based study. Psychosom Med 2002;64:6–12.
9. Jiang W, Kuchibhatla M, Cuffe MS, Christopher EJ, Alexander JD, Blazing MA, Gaulden LH, Califf RM, Krishnan RR, O’Connor CM. Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation 2004;110:3452–3456.
10. Damen NL, Pelle AJ, Szabo BM, Pedersen SS. Symptoms of anxiety and cardiac hospitalizations at 12 months in patients with heart failure. J Gen Intern Med 2012;27:345–350.
11. Cleland JG, Swedberg K, Follath F, Kornajad M, Cohen-Solal A, Aguilar JC, Diez R, Gavazzi A, Hobbs R, Korekiewicz J, Madera HC, Mosseyev VS, Preda I, van Gilst WH, Widimsky J, Freemanite N, Eustagh J, Mason J. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442–463.
12. Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002;4:371–422.
13. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008;52:428–34.
14. Kuznetsova T, Herbots L, Lopez B, Jin Y, Richart T, Thijs L, Gonzalez A, Herrrogs MC, Fagard RH, Diez J, Staessens JA. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009;2:105–112.
15. Kop WJ, Synowski SJ, Gottlieb SS. Depression in heart failure: biobehavioral mechanisms. Heart Fail Clin 2011;7:23–38.
16. Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress. Lancet 2007;370:1089–1100.
17. Garfield LD, Scherrer JR, Hauptman PJ, Freedland KE, Chrysucul T, Babasubramanian S, Carney RM, Newcomer JW, Owen R, Bucholz KK, Lustman PJ. Association of anxiety disorders and depression with incident heart failure. Psychosom Med 2014;76:126–136.
18. Kroksstad S, Langhammer A, Hveem K, Holmen T, Midttjell K, Steine T, Bratberg G, Hegde A, Holmen J. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol 2013;42:968–977.
19. Nauman J, Janszky I, Vatten LJ, Wisløff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011;306:2579–2587.
20. Myklesten A, Stordal E, Dahl AA. Hospital Anxiety and Depression (HAD) scale: factor structure, item analyses and internal consistency in a large population. Br J Psychiatry 2001;179:540–544.
21. Bjelland I, Lie SA, Dahl AA, Myklesten A, Stordal E, Kramer HC. A dimensional versus a categorical approach to diagnosis: anxiety and depression in the HUNT 2 study. Int J Methods Psychiatr Res 2009;18:128–137.
22. Zigmond AS, Snith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scand 1983;67:361–370.
23. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69–77.
24. Bjelland I, Kroksstad S, Myklesten A, Dahl AA, Tell GS, Tambs K. Does a higher educational level protect against anxiety and depression? The HUNT study. Soc Sci Med 2008;66:1334–1345.
25. Laugsand LE, Strand LB, Plåtou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: a population study. Eur Heart J 2014;35:1382–1393.
26. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Melzaza A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (EICM). Eur J Heart Fail 2008;10:933–989.
27. Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur Heart J 2005;7:787–791.
28. Künler T, Grølsan GH, Kirk V, Bay M, Nielsen OW, Kober L, Tørp-Persen C. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 2008;10:658–660.
29. Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
30. Holmen J, Midttjell K, Kruger Ø, Langhammer A, Holmen T, Bratberg G, Vatten L, Lund-Larsen PG. The Nord-Trøndelag Health Study 1995–97 (HUNT 2): objectives, contents, methods and participation. Norvik Epidemiologi 2003:13:19–32. http://www.msu.no/s/nils.doc_library/get_file?uuid=88003372-dabc-404b-ba61-e1d27656b09f&groupId=13034.
31. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Brynhed H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lépine JP, O’Muircheartaigh C, Larøi F, Olssen G, Mulsant BH, Angermeyer MC, Bourguignon F, Laursen EB, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kopperud R, Leino J, Cierpka M; FCN; The World Health Organization Collaborative Study Group on Cardiovascular Disease Risk Factors. The World Health Organization Collaborative Study on Cardiovascular Disease Risk Factors. European Journal of Epidemiology 2009;24:1101–1112.
32. Thomas S, Osborn R, Squires D, Jun M. International profiles of the health care system 2013. Australia, Canada, Denmark, England, France, Germany, Italy, Japan, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United States. http://www.commonwealthfund.org/_media/Pages/PublicationsFund20Report/2013/Nov/1717_Thomson_intl_profiles_hi_tcare_sys_2013_v2.pdf. 2013 1717.
33. Christensen S, Mogelvang R, Heitmann M, Prescott E. Level of education and risk of heart failure: a prospective cohort study with echocardiography evaluation. Eur Heart J 2011;32:450–458.
34. Herrmann C, Brand-Driehorst S, Buss U, Reger U. Effects of anxiety and depression on 5-year mortality in 5,057 patients referred for exercise testing. J Psychosom Res 2000;48:455–462.

© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Berk M, Williams LJ, Jacila FN, O’Neil A, Pasco JA, Moylan S, Allen NB, Stuart AL, Hayley AC, Byrne ML, Maes M. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200.

Gustad LT, Laugaland LE, Janszky I, Dalen H, Bjerkedst O. Symptoms of anxiety and depression and risk of acute myocardial infarction: the HUNT 2 study. Eur Heart J 2014;35:1394–1403.

Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006;27:2763–2774.

Rosengren A, Hawken S, Ounpuu S, Sliwa K, Yusuf D. Association of psychosocial risk factors with risk of acute myocardial infarction in 11,119 cases and 13648 controls from 52 countries (the INTERHEART study): case–control study. Lancet 2004;364:953–962.

MurphyJM,MonsonRR,OlivierDC,SobolAM,LeightonAH.Affective disorders and mortality. A general population study. Arch Gen Psychiatry 1987;44:473–480.

RonessA,MyklestenA,DahlAA.Help-seeking behaviour in patients with anxiety disorder and depression. Acta Psychiatr Scand 2005;111:51–58.

DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for non-compliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101–2107.

Johansen A, Holmen J, Stewart R, Bjerkedst O. Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. The HUNT study. Norway. Eur J Epidemiol 2012;27:63–72.

Glassman AH, Rodriguez AI, Shapiro PA. The use of antidepressants in patients with heart disease. J Clin Psychiatry 1998;59(Suppl 10):16–21.

Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell R, Racynski JM, Schneiderman N. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:3106–3116.

Stewart JC, Perkins AJ, Callahan CM. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial. Psychosom Med 2014;76:29–37.

Grippo AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress 2009;12:1–21.

Francis GS. Padiophysiology of chronic heart failure. Am J Med 2001;110(Suppl 7A):375–465.

Papageorgiou N, Tousoulis D, Androulakis E, Antoniades C, Tentolouris C, Stefanadis C. Inflammation and right ventricle: the hunting of the missing link. Int J Cardiol 2013;168:3152–3154.

Allgulander C, Lavori PW. Excess mortality among 3302 patients with ‘pure’ anxiety neurosis. Arch Gen Psychiatry 1991;48:599–602.

Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ylberg AS. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol 2001;30(Suppl 1):S30–S34.

Merikangas KR, Zhang H, Avenevoli S, Acharyya S, Neuenschwander M, Angst J. Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch Gen Psychiatry 2003;60:993–1000.

Dekker RL, Lennie TA, Doering LV, Chung ML, Wu JR, Moser DK. Coexisting anxiety and depressive symptoms in patients with heart failure. Eur J Cardiovasc Nurs 2014;13:168–176.

Hare DL, Toukhstsi SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J 2014;35:1365–1372.